

InVivo Therapeutics Holdings Corp.  
One Kendall Square, Suite B14402  
Cambridge, MA 02139

November 17, 2022

**VIA EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Re: InVivo Therapeutics Holdings Corp.  
Registration Statement on Form S-1  
File No. 333-268256  
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, InVivo Therapeutics Holdings Corp. hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-268256), so that it may become effective at 4:00 p.m. on November 21, 2022, or as soon thereafter as practicable.

[Remainder of Page Intentionally Left Blank]

---

Very truly yours,

INVIVO THERAPEUTICS HOLDINGS CORP.

By: /s/ Richard Toselli

Name: Richard Toselli

Title: President and Chief Executive Officer

*Signature Page to Acceleration Request*

---